Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

High loading dose of clopidogrel may overcome effects of CYP2C19 genetic variant in persons with CAD

Sep. 23, 2010

Fixed-dose fenofibrate/pravastatin plus ezetimibe reduces hyperlipidemia in type 2 diabetes

Sep. 23, 2010

First selective Aurora kinase A inhibitors identified

Sep. 23, 2010

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Sep. 22, 2010

Phase III data presented on bisoprolol vs. carvedilol in elderly subjects with CHF

Sep. 22, 2010

Galapagos develops new phosphodiesterase 1A inhibitors for osteoarthritis

Sep. 22, 2010

Palau Pharma identifies new histamine H4 receptor antagonists

Sep. 22, 2010

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Sep. 22, 2010

SCH-527123 is safe and efficacious in phase II trial in COPD

Sep. 21, 2010

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Sep. 21, 2010

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...